The Effect of Pinaverium Bromide (Dicetel) in Irritable Bowel Syndrome

İRRİTABL BARSAK SENDROMUNDA DICETAL

Prof. Süleyman YALÇIN M.D., Güngör BOZTAŞ M.D., Sadakat ÖZDİL M.D., Zeynel MUNGAN M.D., Oktay YEĞİNSÜ M.D., Yılmaz ÇAKALOĞLU M.D.

Gastroenterohepatology Section, Department of Internal Medicine, Istanbul University Medical Faculty, İSTANBUL

SUMMARY

The effect of pinaverium bromide (Dicetel), an anti-spasmodic agent acting on the gastrointestinal system as an anti-spasmodic agent acting on the gastrointestinal system as investigated in 110 patient with irritable bowel syndrome in a placebo controlled study. Hundred patients were treated with pinaverium bromide (3x50 mg/day) tablets and ten patients with placebo for two weeks. We observed that pinaverium bromide was significantly effective in irritable bowel syndrome (p<0.01). It was not effective in the patients who had additional organic gastrointestinal disease. A few adverse reactions were seen in the patients who used pinaverium bromide. We conclude that pinaverium bromide is a safely and effective drug in the treatment of irritable bowel syndrome.

Key Words: Irritable bowel syndrome, Pinaverium bromide

Irritable bowel syndrome (IBS) is a motor disorder consisting of altered bowel habits, abdominal pain, and the absence of detectable organic pathology. Symptoms are markedly influenced by psychological factors and stressful life situations (1).

The incidence of IBS has been shown between 15 to 20% in different studies (2,3). Although in some-patients symptoms are very slight, in western countries 20-50% of patients can be diagnosed IBS who refers to gastroenterology clinics (4,5).

Organic disorders should be excluded when IBS diagnosed because there are similarities between IBS and organic disorders of gastrointestinal system. Therefore, diagnosis of IBS is very costly for patients and for social warfare organizations.

Manning et al (6) confirmed that decrease in the abdominal pain after bowel movement, increases in the bowel movement with abdominal pain and findings as distention is more frequent in IBS more than they are in organic disorders. Abdominal pain, flatulence, diarrhea-constipation, presence of mucus in stool has been shown more significantly in IBS by Kruis et al (7).

Pathogenesis of IBS is not clarified yet, but there are gastrointestinal motility abnormalities in IBS. Symptoms of IBS appear after or during period of stress and emotional tension (1,8). Motility abnormalities have been shown in colon and also in small intestine (9).

Submitted: 23.6 1992 Accepted: 3.8.1992

Correspondence: Prof.Dr. Süleyman YALÇIN
Gastroenterohepatology Section
Department of Internal Medicine
Istanbul Medical Faculty
Capa 34390, İSTANBUL
Close physician-patient relationship is very important for improvement of emotional situation in the treatment of IBS. Medical therapy is necessary to reduce abdominal pain and distention, especially during the symptomatic periods. Pinaverium bromide (PB) is a calcium channel blocker that affects locally and minimally absorbed in the gastrointestinal tract. It selectively shows antispasmodic effect on intestinal smooth muscle, therefore, it has been used in the treatment of IBS (10).

In this study we investigated the effect of PB in IBS patients in a placebo controlled study.

MATERIALS AND METHODS

In this study 110 IBS patients were evaluated. Hundred patients were treated with PB and 10 patients with placebo as a control group.

In the treatment group 70 patients were female and 30 patients were male (F/M:7/3) and mean ages were 42 in females and 33 in males. In placebo group, there were 7 females and 3 males, and mean ages were 39 and 40 in female and male patients, respectively.

In both groups, dyspepsia, pain, gas, constipation, diarrhea and nausea were asked and answers were recorded. All patients were evaluated by endoscopic and radiological examinations. Accompanying disorders were also recorded.

Patients were treated with PB (3x50 mg/day) or placebo (3x1/day) for two weeks. Responses to therapy were evaluated as "very well", "well", "mild" and "no response". Results were statistically compared with chi-square test.

RESULTS

In treatment group 10 patients were excluded from the study. 4 patients due to self discontinuation of therapy and 6 patients due to adverse effects. In this group 30 patients responded very well, 24 patients well, 21 mildly and 15 patients did not respond. In control group 2 patients responded very well and 1 patient mildly. Seven patients had no difference in their symptoms after treatment (Table 1).

The improvement rates were 75% in treatment and 30% in the control group. The difference between groups was statistically significant (p<0.01) (Table 2). In treatment group 15 cases did not respond. Eleven of these 15 patients showed additional gastrointestinal disease (Table 3).

Adverse effects in 6 patients were skin rash in 3, dizziness in 2 and pruritis in 1.

DISCUSSION

Irritable bowel syndrome is a functional disease of intestine and seen very frequently in all populations. The main cause of the disease is not well known but alterations in small and large intestinal motility that can be affected by psychological factors are very important (9). Psychotherapy and hypnotherapy need long time for this chronic disease. Medical therapy is necessary for the urgent symptoms as abdominal distention, pain and altered bowel habit. Drugs having antispasmodic or anticholinergic effects are being commonly used in the treatment of IBS (11). PB is an antispasmodic drug absorbed minimally from gut. Passaretti et al (9) had shown a decrease with local effect of rectal PB in the colon motility stimulated by neostigmine. This study also confirms PB’s local action when given by oral route. Bouchoucha et al (12) have shown that PB decreases the frequency of jejunal contractions in IBS patients. Awad et al (13) found that PB is effective by decreasing the electrical and mechanical responses of gastrointestinal tract in IBS patients. In a multicenter clinical trial, PB treatment had shown clinical improvement in 90%, tolerated by 96.3% and side effect in 3.7% of IBS patients (14).

In our clinical trial, clinical improvement was 75%. Eleven patients did not respond because of additional gastrointestinal diseases. These results were similar to the results of the multi-centered studies in the literature. Also, we couldn't assess any side effect as those

<table>
<thead>
<tr>
<th>Table 1. Treatment results in both groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Respond</td>
</tr>
<tr>
<td>--------</td>
</tr>
<tr>
<td>PB* n:100</td>
</tr>
<tr>
<td>Placebo n:10</td>
</tr>
</tbody>
</table>

*Pinaverium bromide, f discontinuation of therapy.

<table>
<thead>
<tr>
<th>Table 2. Overall improvement in both groups</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pinaverium bromide n:100</td>
</tr>
<tr>
<td>Placebo n:10</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Table 3. Associated diseases in non responders</th>
</tr>
</thead>
<tbody>
<tr>
<td>IBS+Duodenal ulcer</td>
</tr>
<tr>
<td>IBS+Cholecystopathy</td>
</tr>
<tr>
<td>IBS+Psychologic disorders</td>
</tr>
</tbody>
</table>
seen with anticholinergic drugs in our IBS patients. This can be explained by minimal absorption of PB from gastrointestinal tract.

As a result, PB can be used in IBS safely and effectively, since it is a drug that has minimal absorption from gastrointestinal tract and has regulatory effects on the motility of small and large intestine by local action.

REFERENCES


